|
17.11.2016 16:31:00
|
Abbott Laboratories -- Moody's assigns Baa3 to Abbott's new senior notes; existing ratings remain on review for downgrade
New York, November 17, 2016 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to Abbott Laboratories' proposed senior unsecured note offering. The rating outlook on the new notes is stable. Proceeds will largely be used to help fund the acquisition of St. Jude Medical, Inc. Abbott has not yet received regulatory approvals for the St. Jude deal, including that from the Federal Trade Commission.
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.